3-allyl-5-fluorosalicylaldehyde | 1554476-84-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-allyl-5-fluorosalicylaldehyde
• 英文别名: 5-fluoro-2-hydroxy-3-(2-propenyl)benzaldehyde；3-allyl-5-fluoro-2-hydroxybenzaldehyde；3-Allyl-5-fluorosalicylaldehyde；5-fluoro-2-hydroxy-3-prop-2-enylbenzaldehyde
• CAS: 1554476-84-4
• 化学式: C₁₀H₉FO₂
• 分子量: 180.179
• InChiKey: VKTFKPIDVPDCGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-allyl-5-fluorosalicylaldehyde 在 二苯硫醚 氢气 、 乙酸乙酯 作用下， 以 乙酸乙酯 为溶剂， 反应 16.0h， 以to afford aldehyde 47e (991 mg, 89.3%) as a yellow oil的产率得到5-fluoro-2-hydroxy-3-propylbenzaldehyde
  参考文献：
  名称：

  PARTICULATE DRUG DELIVERY METHODS

  摘要：

  本发明提供了可用于调节某些酶的化合物和组合物。这些化合物和组合物可以诱导细胞死亡，特别是癌细胞死亡。本发明还提供了合成和使用这些化合物和组合物的方法，包括在治疗癌症和选择性诱导细胞凋亡方面使用这些化合物和组合物的方法。

  公开号：

  US20150210659A1
• 作为产物：
  描述：

  2-(allyloxy)-5-fluorobenzaldehyde 以48.3%的产率得到3-allyl-5-fluorosalicylaldehyde
  参考文献：
  名称：

  [EN] ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS
  [FR] COMPOSÉS ET COMPOSITIONS ACTIVANT DES ENZYMES

  摘要：

  这项发明提供了用于调节某些酶的化合物和组合物。这些化合物和组合物可以诱导细胞死亡，特别是癌细胞死亡。该发明还提供了合成和使用这些化合物和组合物的方法，包括在治疗癌症和选择性诱导细胞凋亡中使用这些化合物和组合物的方法。

  公开号：

  WO2014022858A1

文献信息

• MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF
  申请人：Zhejiang Hisun Pharmaceutical Co., Ltd.

  公开号：EP3974434A1

  公开（公告）日：2022-03-30

  Provided are a macrolide derivative represented by formula (I), a preparation method thereof, and an application of the macrolide derivative as an inhibitor of one or more protein kinases of TRK, ALK and ROS1,

  提供了一种由化学式(I)表示的大环内酯衍生物，其制备方法以及将该大环内酯衍生物作为TRK、ALK和ROS1蛋白激酶的抑制剂的应用。
• Enzyme-activating compounds and compositions
  申请人：The Board of Trustees of the University of Illinois

  公开号：US09249116B2

  公开（公告）日：2016-02-02

  The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.

  本发明提供了一些化合物和组合物，用于调节某些酶的作用。这些化合物和组合物可以诱导细胞死亡，特别是癌细胞死亡。本发明还提供了化合物和组合物的合成和使用方法，包括在治疗癌症和选择性诱导细胞凋亡中使用化合物和组合物的方法。
• ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS
  申请人：The Board of Trustees of the University of Illinois

  公开号：US20160176833A1

  公开（公告）日：2016-06-23

  The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.

  这项发明提供了用于调节某些酶的化合物和组合物。这些化合物和组合物可以诱导细胞死亡，特别是癌细胞死亡。该发明还提供了合成和使用这些化合物和组合物的方法，包括在治疗癌症和选择性诱导细胞凋亡中使用这些化合物和组合物的方法。
• [EN] MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF<br/>[FR] DÉRIVÉS DE MACROLIDES, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR APPLICATION<br/>[ZH] 大环类衍生物、及其制备方法和用途
  申请人：ZHEJIANG HISUN PHARM CO LTD

  公开号：WO2020233645A1

  公开（公告）日：2020-11-26

  式(I)所示的大环类衍生物、其制备方法及其作为TRK、ALK、ROS1中的一种或多种蛋白激酶抑制剂的用途。
• Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics
  作者：Howard S. Roth、Rachel C. Botham、Steven C. Schmid、Timothy M. Fan、Levent Dirikolu、Paul J. Hergenrother

  DOI：10.1021/acs.jmedchem.5b00413

  日期：2015.5.14

  Procaspase-activating compound 1 (PAC-1) is an o-hydroxy-N-acylhydrazone that induces apoptosis in cancer cells by chelation of labile inhibitory zinc from procaspase-3. PAC-1 has been assessed in a wide variety of cell culture experiments and in vivo models of cancer, with promising results, and a phase 1 clinical trial in cancer patients has been initiated (NCT02355535). For certain applications, however, the in vivo half-life of PAC-1 could be limiting. Thus, with the goal of developing a compound with enhanced metabolic stability, a series of PAC-1 analogues were designed containing modifications that systematically block sites of metabolic vulnerability. Evaluation of the library of compounds identified four potentially superior candidates with comparable anticancer activity in cell culture, enhanced metabolic stability in liver microsomes, and improved tolerability in mice. In head-to-head experiments with PAC-1, pharmacokinetic evaluation in mice demonstrated extended elimination half-lives and greater area under the curve values for each of the four compounds, suggesting them as promising candidates for further development.